This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Update: Fisher Scientific to Buy PSS World Medical in Stock Deal

Updated from 9:41 a.m. EDT

Fisher Scientific International (FSH), the top seller of science equipment and supplies in the world, said Thursday that it will buy troubled medical supplies distributor PSS World Medical (PSSI) in a stock deal valued at about $840 million.

PSS also reported fourth-quarter results that drastically missed Wall Street's expectations. Its financial troubles, however, underscore the reason the company put itself up for sale in January.

Shares of Fisher ended down 9 9/16, or 25%, to 28 7/16 in Thursday trading, while shares of PSS fell 2 13/32, or 24%, to 7 15/32.

PSS shares rose 42% between Jan. 25, the day the company proclaimed it was for sale, and Wednesday. In the year before Jan. 25, PSS shares had dropped 59%.

Under the terms of the agreement, Fisher will pay 0.3121 a share of its stock for each share of PSS. Based on Fisher's closing price Wednesday, that translates to stock valued at $11.86, a 20% premium over PSS' closing price Wednesday.

That premium may seem high in light of PSS' results. Those results revealed that "operating problems are deeper than expected and the financials are much messier than expected," said David Risinger, an analyst at Merrill Lynch. He rates PSS a near-term and long-term accumulate and his firm has done no underwriting for the company.

The decision to sell PSS came after the Jacksonville, Fla.-based company reported disappointing third-quarter results, "the third major disappointment in the past two years," Risinger said. "That was the final straw for the management team and board of directors."

One of the major problems concerned Gulf South Medical Supply, a supplier to nursing homes acquired by PSS in 1998. "They were never able to get that acquisition to run correctly," Risinger commented. "There were operating difficulties. Also, the long-term care market has been experiencing severe financial pressure that's made it a difficult business to operate in."

Patrick Kelly, chairman and chief executive of PSS, and Hugh Brown, a member of PSS' board of directors, will both join the Fisher board of directors.

The transaction is expected to be completed in the fourth quarter.

The acquisition enables Fisher, based in Hampton, N.H., to expand into a new market, health care, that is related to its existing business. The combined company projects revenue of $4.8 billion, Ebitda (earnings before interest, taxes, depreciation and amortization) of $352 million and earnings per share of $1.75 for fiscal year 2001.

Fisher "has a proven track record of improving the performance of troubled companies," Risinger added. "And it knows how to run distribution companies."

The transaction is expected to add to earnings per share in the first year, according to Fisher. It is also expected to reduce Fisher's leverage from about 4.7 times Ebitda to 3.9 times Ebitda.

Pre-tax cost savings should amount to about $30 million over the next three years.

Lazard Freres represented Fisher in the deal, while Donaldson, Lufkin & Jenrette Securities represented PSS.

For the fourth quarter ended March 31, PSS reported a net loss of $10.8 million, or 15 cents a diluted share, compared with net income of $12 million, or 17 cents a share, a year earlier. The consensus estimate of analysts polled by First Call/Thomson Financial was income of 21 cents a share.

Including special items, the company reported a loss of $15.7 million, or 22 cents a diluted share.

In addition to special items, PSS took $27.4 million in write-offs and other charges, including $11.5 million for write-offs, reserves and costs from receivables in the nursing home business.

Revenue rose 8% to $443.4 million from $410 million a year ago.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $124.75 -1.13%
FB $80.78 -1.86%
GOOG $524.05 -1.83%
TSLA $206.79 0.04%
YHOO $44.45 -2.91%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs